Tags

Type your tag names separated by a space and hit enter

Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan.
Eur J Haematol. 2008 Mar; 80(3):251-7.EJ

Abstract

Cytomegalovirus (CMV) disease is one of the major infectious complications after allogeneic hematopoietic stem cell transplantation (SCT). Several studies have shown that CMV-seropositive patients have a substantial survival disadvantage after bone marrow transplantation (BMT) or peripheral blood SCT (PBSCT). Between August 1998 and February 2006, 101 adult patients underwent myeloablative cord blood transplantation (CBT) from unrelated donors at our institution. Sixteen and 85 patients were CMV-seronegative and CMV-seropositive, respectively, prior to CBT. Outcomes of CBT were compared between CMV-seronegative and CMV-seropositive patients. The cumulative incidences of neutrophil engraftment at 60 d after CBT did not differ between CMV-seronegative and CMV-seropositive patients (100% and 94%, P = 0.09); however, the cumulative incidence of platelet engraftment at 100 d was higher in CMV-seronegative patients than CMV-seropositive patients (100% vs. 86%, P < 0.005). The cumulative incidence of CMV antigenemia at 100 d was lower in CMV-seronegative patients than CMV-seropositive patients (0% vs. 77%, P < 0.001); however, the cumulative incidences of CMV disease did not differ between CMV-seronegative and CMV-seropositive patients (0% vs. 1%, P = 0.84). The probabilities of disease-free survival at 2 yr also did not differ between CMV-seronegative and CMV-seropositive patients (92% vs. 72%, P = 0.16). The outcomes of CBT for CMV-seropositive patients as well as CMV-seronegative patients in our series were favorable. This might be due to effective antiviral therapy for CMV infection. Large-scale studies are needed to determine the impact of recipient CMV serostatus on the outcome of CBT for adults.

Authors+Show Affiliations

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. atomonar@ims.u-tokyo.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18081702

Citation

Tomonari, Akira, et al. "Impact of Cytomegalovirus Serostatus On Outcome of Unrelated Cord Blood Transplantation for Adults: a Single-institute Experience in Japan." European Journal of Haematology, vol. 80, no. 3, 2008, pp. 251-7.
Tomonari A, Takahashi S, Ooi J, et al. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol. 2008;80(3):251-7.
Tomonari, A., Takahashi, S., Ooi, J., Tsukada, N., Konuma, T., Kato, S., Kasahara, S., Iseki, T., Yamaguchi, T., Tojo, A., & Asano, S. (2008). Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. European Journal of Haematology, 80(3), 251-7.
Tomonari A, et al. Impact of Cytomegalovirus Serostatus On Outcome of Unrelated Cord Blood Transplantation for Adults: a Single-institute Experience in Japan. Eur J Haematol. 2008;80(3):251-7. PubMed PMID: 18081702.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. AU - Tomonari,Akira, AU - Takahashi,Satoshi, AU - Ooi,Jun, AU - Tsukada,Nobuhiro, AU - Konuma,Takaaki, AU - Kato,Seiko, AU - Kasahara,Senji, AU - Iseki,Tohru, AU - Yamaguchi,Takuhiro, AU - Tojo,Arinobu, AU - Asano,Shigetaka, Y1 - 2007/12/07/ PY - 2007/12/18/pubmed PY - 2008/3/4/medline PY - 2007/12/18/entrez SP - 251 EP - 7 JF - European journal of haematology JO - Eur J Haematol VL - 80 IS - 3 N2 - Cytomegalovirus (CMV) disease is one of the major infectious complications after allogeneic hematopoietic stem cell transplantation (SCT). Several studies have shown that CMV-seropositive patients have a substantial survival disadvantage after bone marrow transplantation (BMT) or peripheral blood SCT (PBSCT). Between August 1998 and February 2006, 101 adult patients underwent myeloablative cord blood transplantation (CBT) from unrelated donors at our institution. Sixteen and 85 patients were CMV-seronegative and CMV-seropositive, respectively, prior to CBT. Outcomes of CBT were compared between CMV-seronegative and CMV-seropositive patients. The cumulative incidences of neutrophil engraftment at 60 d after CBT did not differ between CMV-seronegative and CMV-seropositive patients (100% and 94%, P = 0.09); however, the cumulative incidence of platelet engraftment at 100 d was higher in CMV-seronegative patients than CMV-seropositive patients (100% vs. 86%, P < 0.005). The cumulative incidence of CMV antigenemia at 100 d was lower in CMV-seronegative patients than CMV-seropositive patients (0% vs. 77%, P < 0.001); however, the cumulative incidences of CMV disease did not differ between CMV-seronegative and CMV-seropositive patients (0% vs. 1%, P = 0.84). The probabilities of disease-free survival at 2 yr also did not differ between CMV-seronegative and CMV-seropositive patients (92% vs. 72%, P = 0.16). The outcomes of CBT for CMV-seropositive patients as well as CMV-seronegative patients in our series were favorable. This might be due to effective antiviral therapy for CMV infection. Large-scale studies are needed to determine the impact of recipient CMV serostatus on the outcome of CBT for adults. SN - 1600-0609 UR - https://www.unboundmedicine.com/medline/citation/18081702/Impact_of_cytomegalovirus_serostatus_on_outcome_of_unrelated_cord_blood_transplantation_for_adults:_a_single_institute_experience_in_Japan_ L2 - https://doi.org/10.1111/j.1600-0609.2007.01006.x DB - PRIME DP - Unbound Medicine ER -